Free Online Seminar: Practical Applications from Biomarker Discovery to Clinical Use

Multiplex Approach to Multifactorial Diseases: A New Era in Neurodegenerative Biomarker Research

Olink's neurobiomarker analysis is a proteomics method that allows for the highly sensitive and specific simultaneous measurement of neurodegenerative disease-related proteins from limited samples such as plasma, serum, and cerebrospinal fluid, using Proximity Extension Assay (PEA) technology. Olink Target 48 Neurodegeneration enables the absolute quantification of markers important in neurodegenerative disease research, such as Aß40, Aß42, pTau217, NfL, and GFAP, making it useful for longitudinal studies and inter-facility comparisons. Furthermore, by using Olink Explore HT and Target 96 Neurology, a broad protein profiling analysis including neuroinflammation and synaptic function becomes possible, supporting the identification of novel biomarkers and elucidation of pathological mechanisms. **Effects of Implementation** - Promotion of understanding disease mechanisms through comprehensive analysis of neuroinflammation-related proteins. - Increased efficiency in biomarker discovery and contribution to drug development research. - Ability to measure numerous proteins from a small amount of sample, allowing for effective use of valuable samples.

• Other protein analysis
• Research Antibodies
• Other Protein Research

Analysis platform adopted by the world's largest human proteome study, "UK Biobank-PPP."

Olink Explore HT is a next-generation multiplex proteomics analysis platform that extracts an overwhelming amount of information from small sample volumes. It can simultaneously measure over 5,400 proteins from just 2 µL of diverse samples such as plasma, serum, and CSF, achieving 99.5% high specificity and reproducibility through its unique PEA (Proximity Extension Assay) technology. By combining an automated workflow with NGS readouts, it enables high-precision and efficient analysis, accommodating a wide range of research phases from biomarker discovery to clinical research and drug development. Furthermore, it has been adopted in The UK Biobank Pharma Proteomics Project, the largest human proteome study in the world, demonstrating its performance and reliability in large-scale research projects. In addition to the installation of the equipment in laboratories, it is also available through service providers and Olink analysis services, with our staff supporting the experimental design phase according to research objectives and analysis needs.

• Other protein analysis
• Research Antibodies
• Other Protein Research

Research on neurodegenerative diseases using PEA technology, pioneering with the latest markers and absolute quantification.

Olink Target 48 Neurodegeneration is a high-performance proteomics panel specialized in neurodegenerative disease research. It can simultaneously measure 41 types of proteins, including the latest and important central nervous system biomarkers such as Aß40, Aß42, pTau217, NfL, and GFAP, which are gaining attention in Alzheimer's and Parkinson's disease research. This panel enables the acquisition of absolute quantification (ng/mL) data, which is difficult with other technologies, allowing for data comparison between studies and institutions, as well as high reproducibility in long-term longitudinal studies. With just 1µL of plasma or cerebrospinal fluid, high-sensitivity measurements can be achieved, maximizing the use of valuable clinical samples. Furthermore, by combining analyses with Olink's cytokine panel, it comprehensively captures neurodegeneration and neuroinflammation, significantly enhancing analytical power. The standardized workflow using the Signature Q100 system contributes broadly from basic research to clinical and drug discovery research.

• Analysis and sequencing services
• Other protein analysis
• Research Antibodies

Berry Inc. (Headquarters: Taito-ku, Tokyo; CEO: Hiroshi Nakano) will hold a free online seminar titled "Evolved with AI! - A Comprehensive Explanation of eQMS 'QMSmart' from Basics to Latest Updates," which will explain the overall picture and latest updates of the cloud-based eQMS "QMSmart" with a live screen demo, on August 21, 2026 (Friday) from 14:00 to 15:00. This seminar is aimed at those considering the introduction of eQMS, as well as quality assurance, design development, and manufacturing personnel at medical device manufacturers who feel limited by paper and Excel-based QMS operations, as well as management. Participants will be able to see the evolved QMSmart in its entirety in one hour, following this summer's major update.

Quantum Chemistry Calculation Utilization Seminar ~ Approaches to Solving Challenges in Automotive and Materials Manufacturing ~ Date: August 21, 2026 (Friday) 13:30 – 16:00 Venue: Argographics Co., Ltd. Chubu Office We will hold a seminar in Nagoya to learn about the standard computational chemistry tool 'Gaussian.' This is a valuable opportunity to experience computational chemistry methods tailored for automotive and materials manufacturers. We sincerely look forward to your participation. □ For more details □ (Visit the Hulinks page) https://www.hulinks.co.jp/seminar/gaussian-chubu/

Our company will be exhibiting at the "17th International Logistics Comprehensive Exhibition 2026" held at Tokyo Big Sight. The latest logistics equipment, systems, and information will all be gathered in one place! Daiki Sangyo will be making its debut at this well-known logistics and logistics comprehensive exhibition. We sincerely look forward to your visit. ◆ Exhibition Content (Tentative) Using autonomous mobile robots (AMR) from MiR, we will showcase automation solutions that move logistics sites that have been "given up on." 1) A pallet magazine that automates the unmanned transportation, supply, and stocking of pallets. 2) An AMR cart that can operate even in narrow aisles. 3) AMR operation monitoring that helps with cost-effectiveness analysis. ◆ Contact Information Daiki Sangyo Co., Ltd. Sales Promotion Department TEL (06) 7654-7371 FAX (06) 6533-5449

We are pleased to announce a free webinar focused on the inline analysis devices "ProFoss 2" and "ProcessScan2" from FOSS, where we will introduce the benefits and applications of implementing inline analysis. In the second part, we will also demonstrate how customers can develop and manage calibration curves tailored to their products using FOSS's calibration curve development software "FossCalibrator." This program will be beneficial not only for existing analyses but also for customers considering applications for new products and processes. We welcome participants from a wide range of food industries, including dairy, feed, grains, milling, and general food manufacturing. We look forward to your participation. ■ Date and Time: Thursday, September 3, 2026, 15:00-16:30 ■ Content (Part 1): How Inline Analysis is Changing Manufacturing Sites - Why inline analysis is expected now - Case studies and application images Calibration Curve Development with FossCalibrator - Benefits of developing unique calibration curves - Application methods for inline analysis - Examples of applications for a wide range of products For more details, please download the PDF.

The organization will hold a free seminar in a face-to-face format titled "Explained by Evaluators! Points to Note to Avoid Difficulties in Medical Device Testing and Certification" on August 7, 2026 (Friday) at the Shinagawa Front Building (Tokyo venue) and on August 21, 2026 (Friday) at the Osaka ATC Green Eco Plaza (Osaka venue). To sell medical devices in Japan, it is necessary to proceed with the procedures in accordance with the "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices (hereinafter referred to as the Pharmaceutical and Medical Device Act)." In this seminar, our evaluators will clearly explain common pitfalls in electrical safety testing, EMC testing, and Pharmaceutical and Medical Device Act certification. We encourage you to take advantage of this opportunity.